Compounded vs Brand-Name GLP-1: What the FDA Says (2026)
Every point below comes from two FDA pages we opened and read on November 9, 2026. We do not publish compounded prices, because we have no FDA source for them.
The short answer
Brand-name GLP-1 drugs are approved by the FDA. A compounded GLP-1 is prepared by a pharmacy, is not FDA approved, and is not reviewed by the FDA for safety, effectiveness or quality before it is marketed.
The FDA also says compounded drugs can serve an important medical need for some patients, and that compounding may be appropriate only when an approved drug cannot meet a patient's needs.
Side by side
| Brand-name GLP-1 | Compounded GLP-1 | |
|---|---|---|
| FDA approval | Approved by the FDA. | Not FDA approved. |
| FDA review of safety, effectiveness and quality before marketing | Yes, as an approved drug. | No, per the FDA. |
| When the FDA says it fits | Standard prescription use under the label. | Only when a patient's needs cannot be met by an approved drug. |
| Multi-dose vials | Follow the label. | FDA: discard 28 days after first use, new sterile needle and syringe every dose. |
| Shipping | Follow the label. | FDA: injectable GLP-1s need refrigeration. Do not use a product that arrives warm. |
Adverse event reports the FDA cites
As of May 31, 2026, the FDA had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide. The FDA says these are likely underreported and that causation is not always clear. They are report counts, not rates.
Questions to ask before you pay
- Which pharmacy prepares this product, and is it licensed in my state?
- Why does an FDA-approved drug not meet my needs?
- How will my dose be measured, and who checks the math?
- How is it shipped and kept cold, and what do I do if it arrives warm?
Drug-specific pages: tirzepatide and semaglutide.
Frequently asked questions
Is a compounded GLP-1 FDA approved?
No. The FDA says compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before they are marketed. Brand-name drugs such as Wegovy, Ozempic, Zepbound and Mounjaro are FDA approved.
When does the FDA say compounding may be appropriate?
On its page about unapproved GLP-1 drugs, the FDA says compounding may be appropriate only when a patient's needs cannot be met by an FDA-approved drug. Whether that applies to you is a decision for you and a licensed prescriber.
What dosing problems has the FDA reported?
The FDA says it received reports of adverse events, some requiring hospitalization, linked to dosing errors with compounded injectable semaglutide, from patients measuring incorrect doses and in some cases clinicians miscalculating them. Some reports involved doses above the approved label.
How should I handle a multi-dose vial?
The FDA says to discard a multi-dose vial 28 days after first use, even if medication remains, and to use a new sterile needle and syringe for each dose.
Are products sold "for research purposes" legitimate?
The FDA says products sold as "for research purposes" or "not for human consumption" are being marketed for human use, and warns about counterfeit Ozempic and illegal online sales of semaglutide and tirzepatide.
Regulatory and evidence sources
Opened and checked October 28, 2026 unless a source shows its own date. These are the regulator's own pages. They describe what the regulator says, not what any listed provider offers.
- FDA: FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight LossThe FDA says compounded GLP-1 drugs are not FDA approved and are not reviewed for safety, effectiveness or quality, and that compounding may be appropriate only when a patient's needs cannot be met by an approved drug. Page shows "Content current as of 10/01/2026". Checked November 9, 2026.
- FDA: Understanding the Risks of Compounded DrugsThe FDA says compounded drugs are not FDA approved, are not reviewed for safety, effectiveness or quality before marketing, and can serve an important medical need for some patients. Page shows "Content current as of 06/22/2026". Checked November 9, 2026.